- $1.77bn
- $1.24bn
- $68.56m
Brief: Vir Biotechnology enrolls first patient in late-stage study of its treatment for severe liver infection
Vir Biotechnology Inc reports results for the quarter ended December 31 - Earnings Summary
Brief: Vir Biotechnology Q4 Cash & Investments USD 1,100 Million
U.S. STOCKS ON THE MOVE-Astronics, Nike, Climb Bio
Morgan Stanley upgrades Vir Biotechnology on cancer drugs trial data
U.S. RESEARCH ROUNDUP-Accolade, Costco Wholesale, RH
U.S. STOCKS ON THE MOVE-Chart Industries, Accolade, Carvana
U.S. STOCKS ON THE MOVE-Twilio, L3Harris, Chart Industries
Vir jumps on positive data from early-stage trials for tumor treatments
Brief: Vir Biotechnology Announces Encouraging Safety And Efficacy Data In Ongoing Dose Escalation Trials For Dual Masked T-Cell Engagers VIR-5818 In Solid Tumors And VIR-5500 In mCRPC
US FDA revokes authorization for four COVID antibody drugs (updated)
US FDA revokes authorization for five COVID treatments
Brief: US FDA Revoked Emergency Use Authorization For Certain COVID Drugs As Of Dec 13
U.S. RESEARCH ROUNDUP- Apellis Pharmaceuticals, Energizer Holdings, Walmart
Brief: Vir Biotechnology Says Tobevibart And Elebsiran Achieve 100% Virologic Suppression At Week 24
Vir Biotechnology Inc reports results for the quarter ended in January 1 - Earnings Summary
Brief: Vir Biotechnology Q3 Cash & Investments USD 1,190 Million
Brief: VIR Biotechnology To Provide Business Update And Report Third Quarter 2024 Financial Results On October 31, 2024
Brief: Vir Biotechnology Announces Closing Of Exclusive Worldwide License Agreement With Sanofi For Multiple Potential Best-In-Class Clinical-Stage T-Cell Engagers